Morgans Senior Analyst Scott Power caught up with Robert Proulx, Chief Executive Officer of Imagion Biosystems, who explained with he joined the company and the technology behind it.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce